- Home
- COEP vs ANL Comparison
COEP vs ANL Comparison
Compare COEP & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | COEP | ANL |
|---|---|---|
| Founded | 2017 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.4M | 350.9M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | COEP | ANL |
|---|---|---|
| Price | $12.60 | $8.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 28.1K | ★ 218.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.32 | $0.88 |
| 52 Week High | $21.41 | $12.09 |
Technical Indicators
Market Signals| Indicator | COEP | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 52.34 | 56.84 |
| Support Level | $10.83 | $1.37 |
| Resistance Level | $13.53 | $10.15 |
| Average True Range (ATR) | 0.79 | 0.94 |
| MACD | 0.20 | -0.29 |
| Stochastic Oscillator | 70.51 | 60.20 |
Price Performance
Historical ComparisonAbout COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.